TP53 and acute myeloid leukemia: Given our findings and the poor outcomes known to be associated with this disease group [6] especially in the presence of complex karyotype [15], we suggest that AML patients with TP53-mutated disease be considered to represent a “very adverse” group separate from the ELN 2022 adverse-risk group.